This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Pharma Stocks Trading for Under $2

Columbia Laboratories (symbol) (CBRX) is developing products that utilize its bioadhesive drug delivery in a controlled and sustained manner. For the third quarter ended Sept. 30, the company reported a 79% jump in revenue to $14.2 million following asset sales to Watson and other products sales. Columbia Laboratories swung to net income of $257,622 from a year-earlier loss of $5.8 million.

The company recently said that after successful completion of one of its studies it believes the outcome will have a positive impact on the top-line results of the pivotal Phase III clinical trial in December. Moreover, strong positive data may lead to a $6 to $8 million payment from Watson and facilitate Columbia's filing an NDA in first half of 2011.

The company estimates its cash balance as of Dec. 31, 2010, to be in excess of $20 million. It further added that it expects to move to sustained profitability in the upcoming quarters, realizing the benefits of tax-sheltered income through its significant net operating loss carryforwards.

Earlier this month, The Benchmark reassigned a buy rating to the stock and raised its target price to $4 from $3. Currently, the stock is trading at $1.80, indicating an upside of 125%.

This commentary comes from an independent investor or market observer as part of TheStreet guest contributor program. The views expressed are those of the author and do not necessarily represent the views of TheStreet or its management.
6 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
BPAX $55.05 -1.24%
CBRX $7.75 3.61%
ACAD $38.36 0.00%
BIOD $1.14 0.00%
RPRX $8.43 0.00%


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs